CD8A and cancer: This has been demonstrated by the results of in vitro CD8+ T cell killing experiments (26), where the protein stability of PD-L1 in cancer cells was reduced when a point mutation of Y112 was noted in PD-L1, rendering PD-L1 unable to bind to PD-1 on the membrane surface of CD8+ T cells.